<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <billNumber>3792</billNumber>
    <createDate>2018-12-20T07:25:25Z</createDate>
    <updateDate>2020-09-28T22:59:42Z</updateDate>
    <originChamber>Senate</originChamber>
    <billType>S</billType>
    <introducedDate>2018-12-19</introducedDate>
    <congress>115</congress>
    <recordedVotes />
    <committees>
      <billCommittees>
        <item>
          <systemCode>ssju00</systemCode>
          <name>Judiciary Committee</name>
          <chamber>Senate</chamber>
          <type>Standing</type>
          <subcommittees />
          <activities>
            <item>
              <name>Referred to</name>
              <date>2018-12-19T22:33:01Z</date>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <committeeReports />
    <relatedBills>
      <item>
        <latestTitle>Preserve Access to Affordable Generics Act</latestTitle>
        <congress>115</congress>
        <number>124</number>
        <type>S</type>
        <latestAction>
          <actionDate>2017-01-12</actionDate>
          <text>Read twice and referred to the Committee on the Judiciary.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2018-12-19</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on the Judiciary.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2018-12-19</actionDate>
        <links />
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees />
      </item>
      <actionTypeCounts>
        <referredToCommittee>1</referredToCommittee>
        <introducedInSenate>1</introducedInSenate>
      </actionTypeCounts>
      <actionByCounts>
        <senate>2</senate>
      </actionByCounts>
    </actions>
    <sponsors>
      <item>
        <bioguideId>K000367</bioguideId>
        <fullName>Sen. Klobuchar, Amy [D-MN]</fullName>
        <firstName>Amy</firstName>
        <middleName />
        <lastName>Klobuchar</lastName>
        <party>D</party>
        <state>MN</state>
        <identifiers>
          <lisID>1826</lisID>
          <bioguideId>K000367</bioguideId>
          <gpoId>8249</gpoId>
        </identifiers>
        <byRequestType />
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>G000386</bioguideId>
        <fullName>Sen. Grassley, Chuck [R-IA]</fullName>
        <firstName>CHARLES</firstName>
        <middleName>ERNEST</middleName>
        <lastName>GRASSLEY</lastName>
        <party>R</party>
        <state>IA</state>
        <identifiers>
          <lisID>457</lisID>
          <bioguideId>G000386</bioguideId>
          <gpoId>8316</gpoId>
        </identifiers>
        <sponsorshipDate>2018-12-19</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
    </cosponsors>
    <cboCostEstimates />
    <laws />
    <notes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Administrative law and regulatory procedures</name>
          </item>
          <item>
            <name>Civil actions and liability</name>
          </item>
          <item>
            <name>Competition and antitrust</name>
          </item>
          <item>
            <name>Contracts and agency</name>
          </item>
          <item>
            <name>Federal Trade Commission (FTC)</name>
          </item>
          <item>
            <name>Intellectual property</name>
          </item>
          <item>
            <name>Judicial review and appeals</name>
          </item>
          <item>
            <name>Licensing and registrations</name>
          </item>
          <item>
            <name>Marketing and advertising</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <summaries>
      <billSummaries>
        <item>
          <versionCode>00</versionCode>
          <actionDate>2018-12-19</actionDate>
          <actionDesc>Introduced in Senate</actionDesc>
          <lastSummaryUpdateDate>2019-07-11T16:22:24Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>Preserve Access to Affordable Generics and Biosimilars Act </b></p> <p>This bill amends the Federal Trade Commission Act to authorize the Federal Trade Commission to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exceptions, is presumed to have anticompetitive effects and violates this bill if the filer of an abbreviated new drug (generic) application or a biosimilar biological product application: (1) receives anything of value; and (2) agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar biological product for any period of time. </p>]]></text>
          <updateDate>2018-12-19T05:00:00Z</updateDate>
          <name>Introduced in Senate</name>
        </item>
      </billSummaries>
    </summaries>
    <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
    <titles>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <title>A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufactures from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <parentTitleType />
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Display Title</titleType>
        <parentTitleType />
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <parentTitleType />
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <amendments />
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2018-12-19T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-115s3792is/xml/BILLS-115s3792is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2018-12-19</actionDate>
      <text>Read twice and referred to the Committee on the Judiciary.</text>
      <links />
    </latestAction>
    <calendarNumbers />
    <version>1.0.0</version>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

